Tuesday, March 20, 2018 8:35:10 AM
Momenta Pharmaceuticals Announces Presentation of Data Supporting Sialylation Platform
(Ref: GlobeNewswire)
May 2nd, 2014
Excerpts:
Momenta has thoroughly characterized a wide range of IVIg preparations to understand the detailed composition of this plasma-derived product. Using molecular, cellular, and animal models of disease, supplemented by an analysis of samples from human patients treated with IVIg, the company has developed a detailed understanding of the biological basis for the therapeutic effects of IVIg. Momenta scientists now have a broad and comprehensive understanding of the composition of IVIg and its mechanism of action as an anti-inflammatory therapeutic. This research has informed the company's approach to the rational design of several novel, differentiated therapeutic agents.
Dr. Manning will present data that demonstrate the enhanced anti-inflammatory activity of these sialylated agents across a broad range of animal models of autoimmune disease, including inflammatory arthritis, immune thrombocytopenic purpura (ITP), pemphigus, and experimental autoimmune encephalomyelitis (EAE).
http://www.firstwordpharma.com/node/1207611?tsid=17#axzz5A3Y8XHIg
May 5, 2015 PEGS/BOSTON
Selective Modulation of Fc Receptors for Improved Therapy of Orphan Autoimmune Diseases: Lessons from IVIg
Unpublished data: Tony Manning, Ph.D., Vice President, Research, Momenta Pharmaceuticals
Based on extensive characterization of the mechanism of action of IVIg, both in animal models and in humans we rationally designed a series of recombinant drug candidates with the potential to deliver improved therapeutic benefit compared to IVIg. These agents are termed Selective Immunodulators of Fc Receptors (SIF’s), and they selectively modulate the activity of members of the Fcg receptor family. In cell and animal models of immune-complex-mediated autoimmunity, SIF’s display up to 500-fold greater potency than IVIg.
http://www.pegsummit.com/uploadedFiles/PEGS/Agenda/15/PEGS_Final_E.pdf
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM